← The Library
The world · a living book
Longevity & Healthspan
What actually has evidence for a longer healthspan — and what’s hype dressed as science.
2 chaptersupdated July 2026sources linked in every chapter
The story so far
The honest headline of longevity science in 2026 is that the biggest real advance isn’t a fountain-of-youth pill — it’s the GLP-1 drugs, which in rigorous trials cut heart attacks, strokes and deaths in obese people. Money keeps pouring into ambitious biotech, and the first human test of cellular reprogramming began this year, but that’s early safety work, not proof.
The buzziest supplements keep disappointing. The best-evidenced tools remain, boringly, sleep, movement and diet — done consistently. This book tracks the line between what works and what sells. The newest twist: early, still-preliminary evidence that a GLP-1 may slow the aging clock itself.
Chapter 1 · July 2026
What has evidence, and what just has hype
Start with the one thing that’s genuinely strong. In the SELECT trial of more than 17,000 obese patients without diabetes, semaglutide cut death from any cause by about 19% and major cardiovascular events by 20%. That’s the best human evidence any metabolic drug has ever produced for broad mortality benefit, and it’s why a 2025 Nature Biotechnology commentary asked, seriously, whether GLP-1s are the first real longevity drugs. A pill version, orforglipron, cleared Phase 3 and is heading to market — which means access is about to widen dramatically.
The reality checks
The same class also failed where it was hyped: semaglutide flatly did not slow Alzheimer’s in the large EVOKE trials, and the program was shut down. That pattern — metabolic benefit that doesn’t automatically become brain benefit — is the through-line of honest longevity reading. Meanwhile taurine, the viral 2023 “anti-aging biomarker,” was debunked by an NIH study in 2025 that found it doesn’t reliably decline with age at all.
The money and the moonshots
Funding stayed hot despite a broader biotech bust. Retro Biosciences raised at a $1.8 billion valuation; NewLimit closed a $435 million round at $3.1 billion; Altos remains best-funded at over $3 billion. The first-ever human trial of cellular reprogramming — partial Yamanaka factors, the David Sinclair lineage — got FDA clearance and began dosing in age-related eye disease. But note what that is: a first-in-human safety trial, not evidence you can act on. And the cautionary tale sits right beside it — AbbVie began winding down its decade-long, multi-billion-dollar Calico partnership with no approved product.
The unglamorous winners
Converging 2026 reviews keep landing on the same boring truth: sleep quality and physical activity are the strongest behavioral levers on healthy aging, and modest, combined changes beat any single heroic intervention. Aging “clocks” like DunedinPACE are getting better at measuring biological age, but a large 2025 comparison found no single clock is best across diseases — they’re research-grade, not ready to guide your personal choices. One clean policy shift worth knowing: the FDA moved to drop the decades-old “black box” warning on menopausal hormone therapy, reflecting evidence that for women starting within about ten years of menopause, the benefits outweigh the risks.
The open questions
Rapamycin: take it, or wait?
PromisingThe PEARL trial found low-dose rapamycin safe over 48 weeks with gains in lean muscle and reduced pain; it’s the most reliable lifespan extender in mice.
PEARL trial (Aging) Ahead of the evidenceNo human trial has ever shown it extends lifespan, PEARL missed its primary endpoint, and off-label use carries real risks like elevated glucose and impaired healing.
Geroevidence review NAD+ / NMN supplements: worth it?
The optimistic readMore than a dozen human trials confirm NMN and NR safely raise blood NAD+ levels, with early metabolic signals.
Trial review The skeptical readA 2025 meta-analysis of ten trials found no benefit for muscle, strength or function, and NIH scientists warn there’s no controlled data behind the pricey IV drips.
NPR Chapter 2 · July 2026
A first signal that a GLP-1 may slow the clock itself
The GLP-1 story picked up a genuinely new thread in June. Researchers at UC San Diego reported the first randomized, placebo-controlled evidence that semaglutide slows biological aging as measured by epigenetic “clocks.” In a 32-week trial, participants on the drug showed about a 9% slower pace of aging on the DunedinPACE clock and lower scores on PCGrimAge, a clock tied to all-cause mortality risk; a companion pilot found that roughly half of treated participants lengthened their telomeres and tended to walk faster.
Read the fine print
This is an early signal, not a verdict. The aging measures were a post hoc, exploratory analysis of a small trial — about 45 people on the drug and 39 on placebo — run in adults with HIV-associated lipohypertrophy, a specific population. And as this book’s first chapter noted, epigenetic clocks are still research-grade tools: a 2025 comparison found no single clock is best across diseases, so a clock moving is a lead to chase, not proof you should act. The larger test is already running — SURMOUNT-MMO, a roughly 15,000-person tirzepatide trial built around morbidity and mortality endpoints rather than weight — but its results are not yet in.
The open question
Does this change what anyone should do?
A real firstIt’s the first randomized, placebo-controlled hint that a widely used drug nudges multiple aging clocks in the right direction at once.
UC San Diego Easy to oversellA post hoc analysis of fewer than 90 people in one narrow population, on unvalidated surrogate markers, is a promising lead stretched thin when it becomes a longevity headline.
Longevity or Bullshit A living book: chapters are dated and grow as the story develops. Nothing is deleted — the record just gets longer.